肾移植患者他克莫司血药浓度影响因素的研究进展

doi:10.3969/j.issn.1672-3384.2016.05.002

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (572 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要他克莫司作为一种强效免疫抑制剂，被广泛应用于肾移植术后的抗排斥治疗。但其治疗窗窄，血药浓度个体差异大，且移植术后各时间段的目标浓度范围不同，需密切监测血药浓度，以期保证疗效，减少不良反应的发生。笔者全面探讨肾移植术后患者他克莫司血药浓度的影响因素，为他克莫司的治疗药物监测和剂量调整提供参考。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	陈超阳
	周颖
	吴丽瑶
	赵侠
	崔一民

关键词 ：肾移植, 他克莫司, 血药浓度, 影响因素

Abstract：As a potent immunosuppressant, tacrolimus has been widely used as immunosuppressive therapy after kidney transplant.However, due to its narrow therapeutic window, large individual variability in plasma concentrations and different target concentration rang esin different postoperative periods, it is necessary to closely monitor blood concentration of tacrolimus in order to ensure efficacy and reduce adverse reactions. This article fully explored factors influencing tacrolimus blood concentrations in renal transplant recipients, so as to provide a reference for the therapeutic drug monitoring and dosage adjustment of tacrolimus.

Key words： renal transplant Tacrolimus blood concentration influencing factors

收稿日期: 2016-06-06

:	R969.1
	R699.2

通讯作者: 崔一民 E-mail: chenchaoyang_99@163.com

引用本文:

陈超阳, 周颖, 吴丽瑶, 赵侠, 崔一民. 肾移植患者他克莫司血药浓度影响因素的研究进展[J]. 临床药物治疗杂志, 2016, 14(5): 7-11.
CHEN Chao-yang, ZHOU Ying, WU Li-yao, ZHAO Xia, CUI Yi-min. Research progress on influencing factors of tacrolimus concentration in patients undergoing renal transplant. CLINICAL MEDICATION JOURNAL, 2016, 14(5): 7-11.

链接本文:

http://www.lcywzlzz.com/CN/10.3969/j.issn.1672-3384.2016.05.002 或 http://www.lcywzlzz.com/CN/Y2016/V14/I5/7

[1] 刘龙山, 王长希. 他克莫司用于肾移植临床治疗的进展[J]. 世界临床药物, 2014, 35(3): 134-140.
[2] 张弋, 白帼珍, 薛芳菁, 等. 他克莫司在儿童肝移植患者中的血药浓度及影响因素[J]. 中国医院药学杂志, 2008, 28(19): 1650-1653.
[3] Kidney Disease: Improving Global Outcomes (KDIGO)Transplant Work Group. KDIGO clinical practice guideline forthe care of kidney transplant recipients[J]. Am J Transplant, 2009, 9(Suppl 3): S1-S155.
[4] 杨云, 颜耀东, 刘茵, 等. 7 种药物有效血药浓度参考范围的探讨[J]. 临床药物治疗杂志, 2015, 13(2): 14-18.
[5] Velickovi?-Radovanovi? R, Mikov M, Paunovi? G, et al. Gender differences in pharmacokinetics of tacrolimus and their clinical significance in kidney transplant recipients[J].Gend Med, 2011,8(1):23-31.
[6] Ran?i? N, Dragojevi?-Simi? V, Vavi? N, et al. Tacrolimus concentration/dose ratio as a therapeutic drug monitoring strategy:the influence of gender and comedication[J].Vojnosanit Pregl, 2015,72(9):813-822.
[7] 张鑫, 刘志红, 郑敬民, 等. 肾移植患者他克莫司血药浓度的影响因素[J]. 肾脏病与透析肾移植杂志, 2005, 14(4): 333-338.
[8] 魏筱华, 段舟萍, 温金华, 等. 非遗传因素（年龄、性别）对肾移植患者他克莫司药物浓度影响的研究[J]. 实用临床医学, 2014,15(1): 1-2.
[9] Rodrigo E, de Cos M A, Sánchez B, et al. High initial blood levels of tacrolimus in overweight renal transplant recipients[J].Transplant Proc, 2005, 37(3):1453-1454.
[10] 何艳玲, 莫小兰, 吴端仪, 等. 肾病综合征患儿他克莫司血药浓度影响因素分析[J]. 今日药学, 2016, 26(1): 46-50.
[11] Hustert E, Haberl M, Burk O, et al. Thegenetic determinants of the CYP3A5 polymorphism[J]. Pharmacogenetics, 2001, 11(9): 773-779.
[12] Xie H E, Wood A J, Kim R B, et al. Genetic variability in CYP3A5 and its possible consequences[J]. Pharmacogenomics, 2004, 5(3): 243-272.
[13] Niioka T, Kagaya H, Saito M, et al. Capability of utilizing CYP3A5 polymorphisms to predict therapeutic dosage of tacrolimus at early stage post-renal transplantation[J].Int J Mol Sci, 2015, 16(1):1840-1854.
[14] Stefanovi? N Z, Cvetkovi? T P, Jevtovi?-Stoimenov T M, et al.Investigation of CYP3A5 and ABCB1 gene polymorphisms in the longterm following renal transplantation: Effects on tacrolimus exposure and kidney function[J].Exp Ther Med, 2015, 10(3):1149-1156.
[15] Kurzawski M, D?browska J, Dziewanowski K, et al. CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus doseadjusted trough concentrations in kidney transplant recipients[J].Pharmacogenomics, 2014, 15(2):179-188.
[16] Rong G, Jing L, Deng-Qing L, et al. Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients[J].Transplant Proc,2010, 42(9):3455-3458.
[17] 席兰艳, 袁洪, 明英姿, 等. CYP3A4~* 1G、CYP3A5~* 3 基因多态性对肾移植后高血压患者他克莫司血药浓度/ 剂量比的影响[J]. 中国临床药理学与治疗学, 2015, 20(12): 1382-1387.
[18] 欧阳萌, 辛华雯, 唐霞, 等. CYP3A4、3A5 基因多态性对肾移植患者术后他克莫司浓度/ 剂量比值的影响[J]. 中国药师, 2014,17(7): 1069-1073.
[19] 李新长, 孟栋良, 龙成美, 等. 肾移植受者CYP3A5 基因多态性对他克莫司血药浓度及疗效的影响[J]. 中国组织工程研究, 2012,16(18):3255-3258.
[20] 张海燕, 张小明, 吴小丽, 等. CYP3A5 基因多态性对中国肾移植受者他克莫司血药浓度和疗效的影响[J]. 器官移植, 2011, 2(6):328-331.
[21] 侯明明, 宋洪涛, 王庆华, 等. 肾移植患者CYP3A5*3 基因多态性对他克莫司血药浓度/ 剂量比和疗效的影响[J]. 中国医院药学杂志, 2010, 30(4): 313-316.
[22] 王明丽, 吴萍, 罗光华, 等. CYP3A 基因多态性与他克莫司血药浓度的相关性研究[J]. 中国药房, 2010, 21(46): 4343-4346.
[23] 何霞, 童荣生.CYP3A4 和CYP3A5 基因多态性对汉族肾移植患者他克莫司血药浓度的影响[J]. 中国药师, 2013, 16(4): 497-501.
[24] Lalan S, Abdel-Rahman S, Gaedigk A, et al. Effect of CYP3A5 genotype, steroids, and azoles on tacrolimus in a pediatric renal transplant population[J].Pediatr Nephrol, 2014, 29(10):2039-2049.
[25] Birdwell K A, Grady B, Choi L, et al. The use of a DNAbiobank linked to electronic medical records to characterizepharmacogenomic predictors of tacrolimus dose requirementin kidney transplant recipients[J]. Pharmacogenet Genomics,2012, 22(1): 32-42.
[26] Sanghavi K, Brundage R C, Miller M B, et al. Genotypeguided tacrolimus dosing in African-American kidney transplant recipients[J]. Pharmacogenomics J, 2015. doi: 10.1038/tpj.2015.87.
[27] Oetting W S, Schladt D P, Guan W, et al. Genomewide association study of tacrolimus concentrations in african american kidney transplant recipients identifies multiple CYP3A5 alleles[J]. Am J Transplant, 2016, 16(2): 574-582.
[28] Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3 Apromoters and characterization of the genetic basis of polymorphic CYP3A5 expression[J]. Nat Genet, 2001, 27(4):383-391.
[29] MacPhee I A, Fredericks S, Tai T, et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation[J].Am J Transplant, 2004,4(6):914-919.
[30] Tavira B, Coto E, Díaz-Corte C, et al. Pharmacogenetics of tacrolimus after renal transplantation: analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes[J].Clin Chem Lab Med,2011, 49(5):825-833.
[31] Elens L, Bouamar R, Hesselink D A, et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients[J].Clin Chem, 2011,57(11):1574-1583.
[32] 张燕青, 陈锦珊, 李金雨, 等. MDR1 基因多态性和单倍体对肾移植术后稳定期患者他克莫司浓度/ 剂量比值的影响[J]. 药学实践杂志, 2015, 33(5): 415-418.
[33] Li Y, Hu X, Cai B, et al. Meta-analysis of the effect of MDR1 C3435 polymorphism on tacrolimus pharmacokinetics in renal transplant recipients[J]. Transpl Immunol, 2012, 27(1): 12-18.
[34]Anglicheau D, Verstuyft C, Laurent-Puig P, et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients[J].J Am SocNephrol, 2003, 14(7):1889-1896.
[35] Li Y, Yan L, Shi Y, et al. CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients[J]. Springerplus, 2015, 23(4):637.
[36] Haufroid V, Wallemacq P, VanKerckhove V, et al. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study[J]. Am J Transplant, 2006, 6(11): 2706-2713.
[37] 张晶晶. POR*28 基因多态性对免疫抑制剂他克莫司临床个体差异影响的研究[D]. 苏州: 苏州大学, 2013: 1-93.
[38] Jannot A S, Vuillemin X, Etienne I, et al. A lack of significant effect of POR*28 allelic variant on tacrolimusexposure in kidney transplant recipients[J]. Ther Drug Monit, 2016, 38(2): 223-229.
[39] Xing J, Zhang X, Fan J, et al. Association between interleukin-18 promoter variants and tacrolimus pharmacokinetics in Chinese renal transplant patients[J]. Eur J Clin Pharmacol, 2015, 71(2): 191-198.
[40] Ogasawara K, Chitnis S D, Gohh R Y, et al. Multidrug resistanceassociated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients[J].Clin Pharmacokinet, 2013, 52(9): 751-762.
[41] Lunde I, Bremer S, Midtvedt K, et al. The influence of CYP3A,PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients[J]. Eur J Clin Pharmacol, 2014, 70(6): 685-693.
[42] 张瑞麟, 李忠东, 刘敏. 肾移植患者血液中他克莫司稳态谷浓度的影响因素分析[J]. 中国医院用药评价与分析, 2012, 12(3): 233-235.
[43] 付绍杰, 王彦斌, 于立新, 等. 肾移植受者他克莫司剂量/ 浓度个体差异影响因素及其变化规律[J]. 南方医科大学学报, 2008,28(12): 2161-2164.
[44] Li J L, Wang X D, Chen S Y, et al. Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective[J].Pharmacogenomics J, 2011,11(4):300-306.
[45] 易鑫, 汪江林, 周亚男, 等. 地尔硫单用及与氨氯地平或非洛地平联用对肾移植受者他克莫司血药浓度/ 剂量比的影响[J]. 中国药房, 2015, 26(15): 2038-2041.
[46] 郭晓伟, 陈刚, 朱兰, 等. 五酯胶囊对肾移植受者他克莫司血药浓度的影响[J]. 华中科技大学学报( 医学版), 2011, 40(1): 95-97.
[47] Kuypers D R, de Jonge H, Naesens M, et al. Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients[J].Pharmacogenet Genomics, 2008, 18(10):861-868.
[48] 朱春丽, 吴家清, 李琴, 等. 肾脏移植患者中厄他培南和他克莫司的药物相互作用研究[J]. 检验医学与临床, 2015, 12(19): 2890-2894.
[49] Rancic N, Dragojevic-Simic V, Vavic N, et al. Tacrolimus concentration/dose ratio as a therapeutic drug monitoring strategy: the influence of gender and comedication[J]. Vojnosanit Pregl, 2015, 72(9): 813-822.
[50] 谢华, 王荣, 武晓玉, 等. 他克莫司血药浓度监测与合理用药分析[J]. 中国药房, 2013, 24(26): 2427- 2429.
[51] 左富姐, 王立明, 闵敏, 等. 绿豆食品降低肾移植患者他克莫司血药谷浓度1 例报告[J]. 器官移植, 2012, 3(2): 106-107.
[52] 滕立臣, 王长希, 陈立中, 等. 腹泻对肾移植受者他可莫司血药浓度的影响[J]. 肾脏病与透析肾移植杂志, 2009, 18(5): 406-409.
[53] Zhu L, Zhang J, Song H, et al. Relationships of related genetic polymorphisms and individualized medication of tacrolimus in patients with renal transplantation[J]. Int J Clin Exp Med, 2015,8(10): 19006-190013.
[54] Wang P, Mao Y, Razo J, et al. Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients[J].Pharmacogenomics, 2010, 11(10): 1389-1402.